Live bevacizumab updates

Live bevacizumab news coverage of developments with the latest updates. Stay on top of latest bevacizumab news stories and find out what just happened, what is going on with bevacizumab. The latest real-time news updates and headlines on bevacizumab
Adding Bevacizumab to Targeted Drug and Chemotherapy Shows Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Lynparza and Imfinzi combo boosts survival in advanced ovarian cancer patients
1/3 of Drug-Resistant Ovarian Cancer Patients Find Remission with Conjugate Therapy
Advanced Cervical Cancer: Pembrolizumab Prolongs Life Span
Plasma GH Predicts Response to Atezolizumab & Bevacizumab in HCC
One of Two Widely Used Macular Degeneration Drugs Outperforms Other at Weaning Patients Off Treatment at One Year
Localising BRCA gene mutations to better treat ovarian cancer
Dana-Farber research supports FDA approval of new therapy for certain patients with ovarian cancer
Lynparza in combination with bevacizumab, and as monotherapy, demonstrates clinically meaningful survival benefit
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
Johns Hopkins Researchers Call for Closing Gap in Collecting Racial and Ethnic Data
How have hepatocellular carcinoma treatments improved?
Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show
New drug combination effective for patients with advanced ovarian cancer
Combination therapies may improve outcomes due to independent, rather than synergistic or additive, drug action
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
RAS reversion in colorectal cancer patients treated with bevacizumab
Atezolizumab and bevacizumab show meaningful responses for malignant peritoneal mesothelioma patients
Early Access continues during coronavirus pandemic
Daily coffee consumption associated with improved survival in patients with metastatic colorectal cancer
Blood pressure drug improves response to cancer therapy
New treatment extends lives of people with most common type of liver cancer
PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Brigham Radiation Oncologists Present Findings at ASTRO 2019
Update on licensing status of Avastin when intended for intravitreal administration
Alvotech and Cipla Gulf Enter Into a Partnership for Commercialization of Key Biosimilar